--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock
Exchange ”) and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents
of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those
defined in the prospectus dated March 20, 2026 (the “Prospectus ”) issued by Hangzhou Diagens Biotechnology Co.,
Ltd. (ʮ̡ ) (the “Company ”).
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer
by any person to acquire, purchase or subscribe for any of the securities of the Company. This announcement is not a
prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described
below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer
Shares should be taken solely in reliance on the information provided in the Prospectus.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale
of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is
not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction
where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or
subscribe for securities in the United States or any other jurisdictions. The Offer Shares have not been, and will not
be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities
Act”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred within the United
States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act
(the “Regulation S ”)) except in transactions exempt from, or not subject to, the registration requirements of the
U.S. Securities Act. The Offer Shares are being offered and sold outside the United States in offshore transactions in
accordance with Regulation S. There will be no public offering of the Offer Shares in the United States.
No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in
relation to the Global Offering.
The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out
in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or
not resident in Hong Kong. Potential investors of the Offer Shares should note that the Sponsor-overall Coordinator
(for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate its obligations under the
Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the
paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds
for Termination ” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is
currently expected to be on Monday, March 30, 2026).


--- page 2 ---
2
Hangzhou Diagens Biotechnology Co., Ltd.
ʮ̡
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
Global Offering
Number of Offer Shares under
the Global Offering
: 7,999,200 H Shares
Number of Hong Kong Offer Shares : 799,950 H Shares
Number of International Offer Shares : 7,199,250 H Shares
Final Offer Price : HK$99.0 per H Share, plus brokerage of
 1.0%, SFC transaction levy of 0.0027%,
 AFRC transaction levy of 0.00015% and
 Hong Kong Stock Exchange trading fee of
 0.00565%
Nominal value : RMB1.00 per H Share
Stock code : 2526
Sole Sponsor, Sponsor-overall Coordinator, Overall Coordinator,
Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager
Overall Coordinator, Joint Global Coordinator,
Joint Bookrunner and Joint Lead Manager
Joint Bookrunners and Joint Lead Managers


--- page 3 ---
3
Hangzhou Diagens Biotechnology Co., Ltd.
ʮ̡
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same
meanings as those defined in the prospectus dated March 20, 2026 (the “Prospectus ”) issued by
Hangzhou Diagens Biotechnology Co., Ltd. (ʮ̡ ) (the “Company ”).
SUMMARY
Warning: In view of high concentration of shareholding in a small number of H
Shareholders, H Shareholders and prospective investors should be aware that the price of
the H Shares could move substantially even with a small number of H Shares traded and
should exercise extreme caution when dealing in the H Shares.
Company information
Stock code 2526
Stock short name DIAGENS-B
Dealings commencement date March 30, 2026*
* see note at the end of the announcement
Price Information
Final Offer Price HK$99.0
Offer Price Range HK$95.6 - HK$112.5
Offer Price Adjustment exercised N/A
Offer Shares and Share Capital
Number of Offer Shares 7,999,200
Number of Offer Shares in the Hong Kong Public Offering 799,950
Number of Offer Shares in the International Offering 7,199,250
Number of issued shares upon Listing 88,879,200


--- page 4 ---
4
Proceeds
Gross proceeds Note HK$791.9 million
Less: Estimated listing expenses payable based on Final Offer
Price HK$72.11 million
Net proceeds HK$719.8 million
Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds,
please refer to the section headed “Future Plans and Use of Proceeds ” of the Prospectus.
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 115,017
No. of successful applications 14,278
Subscription level 1,073.37 times
Reallocation No
No. of Offer Shares initially available under the Hong Kong Public
Offering 799,950
No. of Offer Shares reallocated from the International Offering 0
Final no. of Offer Shares under the Hong Kong Public Offering 799,950
% of Offer Shares under the Hong Kong Public Offering to the Global
Offering 10%
Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to
www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment
for the full list of allottees.


--- page 5 ---
5
INTERNATIONAL OFFERING
No. of placees 120
Subscription level 3.45 times
No. of Offer Shares initially available under the International Offering 7,199,250
No. of Offer Shares reallocated to the Hong Kong Public Offering 0
Final no. of Offer Shares under the International Offering 7,199,250
% of Offer Shares under the International Offering to the Global
Offering 90%
The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the
Offer Shares subscribed by the placees and the public have been financed directly or indirectly
by the Company, any of the Directors, supervisors, chief executive of the Company, controlling
shareholders, substantial shareholders, existing shareholders of the Company or any of its
subsidiaries or their respective close associates; and (ii) none of the placees and the public who
have purchased the Offer Shares are accustomed to taking instructions from the Company, any of
the Directors, supervisors, chief executive of the Company, controlling shareholders, substantial
shareholders, existing shareholders of the Company or any of its subsidiaries or their respective
close associates in relation to the acquisition, disposal, voting or other disposition of Shares
registered in his/her/its name or otherwise held by him/her/it.


--- page 6 ---
6
The placees in the International Offering include the following:
Allotees with Consent Obtained
Investor
Number of Offer
Shares allocated
% of total number
of Offer Shares
% of total issued
share capital after
the Global Offering Relationship
Allottees with consent under paragraph 1C(1) of Appendix F1 to the Listing Rules ( “Placing Guidelines ”) in relation to allocations to a
connected client (1)
Huatai Capital Investment Limited
(“HTCI”)
31,350 0.39% 0.04% HTCI and Huatai
Financial
Holdings (Hong
Kong) Limited
(“Huatai ”) are
group companies
within the same
group
Notes:
(1) For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to a
connected client, please refer to the section headed “Others/Additional Information – Placing to a connected
client with a prior consent under paragraph 1C(1) of the Placing Guidelines ” in this announcement.


--- page 7 ---
7
LOCK-UP UNDERTAKINGS
Controlling Shareholders(As Defined in the Prospectus)
Name
Number of
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (7)
Number of H
shares held in
the Company
subject to
lock-up
undertakings
upon listing Note (7)
% of total
issued H Shares
after the Global
Offering subject
to lock-up
undertakings
upon listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings
Dr. Song Ning
(“Dr. Song ”)Note (1), (2), (3), (4) and (5)
24,293,507 24,293,507 27.33% 27.33% March 30, 2027 Note (6)
Hangzhou Diagens Nuohui
Investment Management
Partnership Enterprise
(Limited Partnership) (ψᅃ
ቇፕሾҳ༟၍ଣΥྫΆุ
(Υྫ ))(“Diagens
Nuohui ”)Note (2)
7,614,901 7,614,901 8.57% 8.57% March 30, 2027 Note (6)
Hangzhou Diagens Nuoda
Technology Management
Partnership Enterprise
(Limited Partnership) (ψᅃ
Ҧ၍ଣΥྫΆุ
(Υྫ ))(“Diagens
Nuoda ”)Note (3)
4,759,247 4,759,247 5.35% 5.35% March 30, 2027 Note (6)
Hangzhou Deqian Technology
Management Partnership
Enterprise (Limited
Partnership) (Ҧ
၍ଣΥྫΆุ (Υྫ ))
(“Deqian Technology ”)
3,530,834 3,530,834 3.97% 3.97% March 30, 2027 Note (6)
Hangzhou Diagens Nuoxin
Investment Management
Partnership Enterprise
(Limited Partnership) (ψᅃ
ቇፕ㒥ҳ༟၍ଣΥྫΆุ
(Υྫ ))(“Diagens
Nuoxin ”)
1,903,668 1,903,668 2.14% 2.14% March 30, 2027 Note (6)
Subtotal 42,102,157 42,102,157 47.37% 47.37%


--- page 8 ---
8
Notes:
(1) Dr. Song beneficially holds 24,293,507 Shares.
(2) Diagens Nuohui, being an ESOP Platform, is managed and controlled by its general partner, Dr. Song.
Diagens Nuohui is owned as to approximately 61.35% by Hangzhou Defeng Acceleration Technology
Management Partnership (Limited Partnership) (Ҧ၍ଣΥྫΆุ (Υྫ )) ( “Defeng
Acceleration ”) as its limited partner, which is in turn owned as to approximately 99.84% by Dr. Song as
its general partner. Diagens Nuohui is owned as to approximately 36.61% by Hangzhou Defeng Origin
Technology Management Partnership (Limited Partnership) (Ҧ၍ଣΥྫΆุ (Υྫ ))
(“Defeng Origin ”) as its limited partner, which is in turn managed by Dr. Song as its general partner and
not owned as to more than 30% by any of its limited partners. Diagens Nuohui is owned as to approximately
1.94% by Hangzhou Defeng Rise Technology Limited Partnership (Ҧ၍ଣΥྫΆุ (Υ
ྫ)), which is in turn managed by Dr. Song as its general partner and not owned as to more than 30% by any
of its limited partners.
As such, under the SFO, each of Dr. Song, Defeng Acceleration and Defeng Origin is deemed to be interested
in the 7,614,901 Shares held by Diagens Nuohui.
(3) Diagens Nuoda is managed by its general partner, Dr. Song. None of the limited partners (not including Dr.
Song who is the general partner) of Diagens Nuoda owns more than 30% of limited partnership interests
therein. As such, under the SFO, Dr. Song is deemed to be interested in the 4,759,247 Shares held by Diagens
Nuoda.
(4) Deqian Technology is managed by its general partner, Dr. Song. And Deqian Technology is owned as to
approximately 99.90% by Hangzhou Dezhi Technology Management Partnership (Limited Partnership) (ψ
Ҧ၍ଣΥྫΆุ (Υྫ )) as the sole limited partner, which is in turn owned as to approximately
76.71% by Dr. Song as its general partner.
As such, under the SFO, each of Dr. Song and Hangzhou Dezhi Technology Management Partnership (Limited
Partnership) is deemed to be interested in the 3,530,834 Shares held by Deqian Technology.
(5) Diagens Nuoxin is managed by its general partner, Dr. Song. And Diagens Nuoxin is owned as to
approximately 62.50% by Mr. GUO Jian ( ெ਄) as its limited partner. None of other limited partners of
Diagens Nuoxin owns more than 30% of partnership interests therein.
As such, under the SFO, each of Dr. Song and Mr. GUO Jian is deemed to be interested in the 1,903,668
Shares held by Diagens Nuoxin.
(6) According to the PRC Company Law, all the Shares held by the existing Shareholders prior to the Global
Offering are subject to a lock-up period of 12 months following the Listing Date.
(7) Calculated based on the assumption that all 80,880,000 Unlisted Shares will be converted into H Shares upon
listing.


--- page 9 ---
9
Other Existing Shareholders (including the Pre-IPO Investors as defined in the “History,
Development and Corporate Structure ” section of the Prospectus)
Name
Number of
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
Number of H
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
% of total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings
Hangzhou Zicheng Investment
Management Limited
Partnership (Limited
Partnership)
(ҳ༟၍ଣΥྫΆ
ุ(Υྫ ))Note (1) 2,539,107 2,539,107 2.86% 2.86%
30 March
2027 Note (2)
Hangzhou Zizhou Investment
Management Limited
Partnership (Limited
Partnership)
(ҳ༟၍ଣΥྫΆ
ุ(Υྫ ))Note (1) 4,694,039 4,694,039 5.28% 5.28%
30 March
2027 Note (2)
Hangzhou Zizheng Investment
Management Limited
partnership (Limited
Partnership)
(ψഓ͍ҳ༟၍ଣΥྫΆ
ุ(Υྫ )Note (1) 1,546,877 1,546,877 1.74% 1.74%
30 March
2027 Note (2)
Ningbo Jiayuan Venture Capital
Limited Partnership (Limited
Partnership)
(ྗᇝ௴ุҳ༟ΥྫΆ
ุ(Υྫ ))Note (1) 3,498,695 3,498,695 3.94% 3.94%
30 March
2027 Note (2)


--- page 10 ---
10
Name
Number of
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
Number of H
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
% of total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings
Guozhong Private Equity
Investment Fund (Xi ’an)
Limited Partnership (Limited
Partnership)
(ږ
(Гτ)ΥྫΆุ (ࠢ
Υྫ))Note (1) 2,959,964 2,959,964 3.33% 3.33%
30 March
2027 Note (2)
Hunan Xiangjiang Liyuan
Jiankun Venture Capital
Limited Partnership (Limited
Partnership)
(ಱϪɢჃ਄㆕௴ุҳ
༟ΥྫΆุ (Υྫ ))Note (1) 2,959,964 2,959,964 3.33% 3.33%
30 March
2027 Note (2)
Nanjing Huarui Ruichuang
Venture Capital Center
(Limited Partnership)
(ԯശြြ௴௴ุҳ༟ʕ
ː(Υྫ ))Note (1) 986,655 986,655 1.11% 1.11%
30 March
2027 Note (2)
Jiaxing Weixin No. 1 Equity
Investment Limited
Partnership (Limited
Partnership)
(ᛆҳ༟Υ
ྫΆุ(Υྫ ))Note (1) 986,655 986,655 1.11% 1.11%
30 March
2027 Note (2)
Qingdao Juancheng Equity
Investment Limited
Partnership (Limited
Partnership)
(ᛆҳ༟ΥྫΆ
ุ(Υྫ ))Note (1) 986,655 986,655 1.11% 1.11%
30 March
2027 Note (2)
Lishui Jingen Private Equity
Limited Partnership (Limited
Partnership)
(ᛆҳ༟ΥྫΆ
ุ(Υྫ ))Note (1) 986,655 986,655 1.11% 1.11%
30 March
2027 Note (2)
Hangzhou Huayun Equity
Investment Limited
Partnership (Limited
Partnership)
(ᛆҳ༟ΥྫΆ
ุ(Υྫ ))Note (1) 197,330 197,330 0.22% 0.22%
30 March
2027 Note (2)


--- page 11 ---
11
Name
Number of
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
Number of H
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
% of total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings
Hangzhou Yuxijin Equity
Investment Limited
Partnership (Limited
Partnership)
(ᛆҳ༟Υྫ
Άุ(Υྫ ))Note (1) 1,479,975 1,479,975 1.67% 1.67%
30 March
2027 Note (2)
Tianjin Binhai Yuanyi Jimao
Private Equity Limited
Partnership (Limited
Partnership)
(ᛆҳ
༟ΥྫΆุ (Υྫ ))Note (1) 1,945,119 1,945,119 2.19% 2.19%
30 March
2027 Note (2)
Tianjin Yuanyi Yongxuan
Enterprise Management
Center (Limited Partnership)
(Άุ၍ଣʕ
ː(Υྫ ))Note (1) 1,945,119 1,945,119 2.19% 2.19%
30 March
2027 Note (2)
Tianjin Yongqian Enterprise
Management Center (Limited
Partnership)
(͑৻Άุ၍ଣʕː (Ϟ
Υྫ))Note (1) 194,512 194,512 0.22% 0.22%
30 March
2027 Note (2)
Hangzhou Hetu No. 6 Private
Equity Limited Partnership
(Limited Partnership)
(ᛆҳ༟Υ
ྫΆุ(Υྫ ))Note (1) 4,491,905 4,491,905 5.05% 5.05%
30 March
2027 Note (2)
Hangzhou Yuhang Jingkai
Private Equity Limited
Partnership (Limited
Partnership)
(ᛆҳ༟ਿ
ΥྫΆุ (Υྫ ))Note (1) 1,296,745 1,296,745 1.46% 1.46%
30 March
2027 Note (2)
Hunan Xiangjiang Liyuan
Jianxiao Venture Capital
Limited Partnership (Limited
Partnership)
(ಱϪɢჃ਄ᖋ௴ุҳ
༟ΥྫΆุ (Υྫ ))Note (1) 648,374 648,374 0.73% 0.73%
30 March
2027 Note (2)


--- page 12 ---
12
Name
Number of
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
Number of H
Shares held in
the Company
subject to lock-
up undertakings
upon listing Note (3)
% of total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon listing
% of
shareholding in
the Company
subject to lock-
up undertakings
upon listing
Last day subject
to the lock-up
undertakings
Jiaxing Qingyulan No. 1
Venture Capital Limited
Partnership (Limited
Partnership)
(ᔝఠ໮௴ุҳ༟
ΥྫΆุ (Υྫ ))Note (1) 383,419 383,419 0.43% 0.43%
30 March
2027 Note (2)
Hangzhou Hefu Private Equity
Limited Partnership (Limited
Partnership)
(ᛆҳ༟ΥྫΆ
ุ(Υྫ ))Note (1) 2,154,451 2,154,451 2.42% 2.42%
30 March
2027 Note (2)
Hangzhou Huarui Ruiyin
Venture Capital Partnership
(Limited Partnership)
(ψശြြვ௴ุҳ༟Υ
ྫΆุ(Υྫ ))Note (1) 947,814 947,814 1.07% 1.07%
30 March
2027 Note (2)
Zhejiang Hongshiliang Group
Jigongjia Wine Co., Ltd.
(ৢ
ʮ̡ )Note (1) 947,814 947,814 1.07% 1.07%
30 March
2027 Note (2)
Subtotal 38,777,843 38,777,843 43.64% 43.64%
Notes:
(1) Please refer to the section headed “History, Development and Corporate Structure {  Principal Terms of the
Pre-IPO Investments ” in the Prospectus for details of the Pre-IPO Investors
(2) According to the PRC Company Law, all the Shares held by the existing Shareholders prior to the Global
Offering are subject to a lock-up period of 12 months following the Listing Date.
(3) Calculated based on the assumption that all 80,880,000 Unlisted Shares will be converted into H Shares upon
listing.


--- page 13 ---
13
PLACEE CONCENTRATION ANALYSIS
Placees*
Number of
H Shares
allotted
Allotment
as % of
International
Offering
Allotment
as % of total
Offer Shares
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
Top 1 879,150 12.21% 10.99% 879,150 0.99%
Top 5 2,545,700 35.36% 31.82% 2,545,700 2.86%
Top 10 3,894,600 54.10% 48.69% 3,894,600 4.38%
Top 25 5,491,350 76.28% 68.65% 5,491,350 6.18%
Notes
* Ranking of placees is based on the number of H Shares allotted to the placees.


--- page 14 ---
14
H SHAREHOLDERS CONCENTRATION ANALYSIS
H Shareholders*
Number of
H Shares
allotted
Allotment
as % of
International
Offering
Allotment
as % of
total Offer
Shares
Number of
H Shares
held upon
Listing
% of total
issued H
Share
capital upon
Listing
Number of
Shares held
upon Listing
Top 1 0 0.00% 0.00% 42,102,157 47.37% 42,102,157
Top 5 0 0.00% 0.00% 65,143,308 73.29% 65,143,308
Top 10 0 0.00% 0.00% 78,170,270 87.95% 78,170,270
Top 25 4,093,500 56.86% 51.17% 84,778,988 95.39% 84,778,988
Notes
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing


--- page 15 ---
15
SHAREHOLDERS CONCENTRATION ANALYSIS
Shareholders*
Number of
H Shares
allotted
Allotment
as % of
International
Offering
Allotment
as % of
total Offer
Shares
Number of
H Shares
held upon
Listing
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
Top 1 0 0.00% 0.00% 42,102,157 42,102,157 47.37%
Top 5 0 0.00% 0.00% 65,143,308 65,143,308 73.29%
Top 10 0 0.00% 0.00% 78,170,270 78,170,270 87.95%
Top 25 4,093,500 56.86% 51.17% 84,778,988 84,778,988 95.39%
Notes
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing


--- page 16 ---
16
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by
the public will be conditionally allocated on the basis set out below:
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT / BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED
OF THE TOTAL
NO. OF SHARES
APPLIED FOR
POOL A
50 62,439 1,873 out of 62,439 to receive 50 Shares 3.00%
100 5,013 167 out of 5,013 to receive 50 Shares 1.67%
150 1,687 58 out of 1,687 to receive 50 Shares 1.15%
200 1,570 57 out of 1,570 to receive 50 Shares 0.91%
250 1,569 58 out of 1,569 to receive 50 Shares 0.74%
300 1,058 41 out of 1,058 to receive 50 Shares 0.65%
350 752 30 out of 752 to receive 50 Shares 0.57%
400 5,549 224 out of 5,549 to receive 50 Shares 0.50%
450 1,008 42 out of 1,008 to receive 50 Shares 0.46%
500 3,247 140 out of 3,247 to receive 50 Shares 0.43%
600 858 39 out of 858 to receive 50 Shares 0.38%
700 628 31 out of 628 to receive 50 Shares 0.35%
800 1,708 87 out of 1,708 to receive 50 Shares 0.32%
900 1,193 63 out of 1,193 to receive 50 Shares 0.29%
1,000 2,389 133 out of 2,389 to receive 50 Shares 0.28%
1,500 1,444 97 out of 1,444 to receive 50 Shares 0.22%
2,000 1,239 98 out of 1,239 to receive 50 Shares 0.20%
2,500 1,041 95 out of 1,041 to receive 50 Shares 0.18%
3,000 828 85 out of 828 to receive 50 Shares 0.17%
3,500 652 74 out of 652 to receive 50 Shares 0.16%
4,000 649 82 out of 649 to receive 50 Shares 0.16%
4,500 547 75 out of 547 to receive 50 Shares 0.15%
5,000 1,356 204 out of 1,356 to receive 50 Shares 0.15%
6,000 757 131 out of 757 to receive 50 Shares 0.14%
7,000 713 141 out of 713 to receive 50 Shares 0.14%
8,000 597 132 out of 597 to receive 50 Shares 0.14%
9,000 651 159 out of 651 to receive 50 Shares 0.14%
10,000 3,031 812 out of 3,031 to receive 50 Shares 0.13%
20,000 1,660 829 out of 1,660 to receive 50 Shares 0.12%
30,000 1,020 746 out of 1,020 to receive 50 Shares 0.12%
40,000 1,244 1,197 out of 1,244 to receive 50 Shares 0.12%
108,097 Total number of Pool A successful applicants: 8,000


--- page 17 ---
17
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS BASIS OF ALLOTMENT / BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED
OF THE TOTAL
NO. OF SHARES
APPLIED FOR
POOL B
50,000 3,420 2,848 out of 3,420 to receive 50 Shares 0.08%
60,000 730 660 out of 730 to receive 50 Shares 0.08%
70,000 476 50 Shares 0.07%
80,000 301
50 Shares plus 15 out of  301 to receive additional 50
Shares 0.07%
90,000 227
50 Shares plus 28 out of  227 to receive additional 50
Shares 0.06%
100,000 614
50 Shares plus 120 out of  614 to receive additional 50
Shares 0.06%
150,000 369
50 Shares plus 205 out of  369 to receive additional 50
Shares 0.05%
200,000 194 100 Shares 0.05%
250,000 107
100 Shares plus 30 out of  107 to receive additional 50
Shares 0.05%
300,000 122 150 Shares 0.05%
399,950 360
150 Shares plus 58 out of  360 to receive additional 50
Shares 0.04%
6,920 Total number of Pool B successful applicants: 6,278


--- page 18 ---
18
As of the date of this announcement, the relevant subscription monies previously deposited in the
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
Investors should contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that consent has been obtained, the
Company has complied with the Listing Rules and guidance materials in relation to the placing,
allotment and listing of the Company ’s H Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees
or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or
purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction
levy, SFC transaction levy and Hong Kong Stock Exchange trading fee payable.


--- page 19 ---
19
OTHERS/ADDITIONAL INFORMATION
Placing to a connected client with a prior consent under paragraph 1C(1) of the Placing
Guidelines
The Company has applied to the Hong Kong Stock Exchange for, and the Hong Kong Stock
Exchange has granted, a consent under paragraph 1C of the Placing Guidelines to permit the
Company to allocate the Offer Shares in the International Offering to a connected client. The
allocation of Offer Shares to such a connected client is in compliance with all the conditions
under the consent granted by the Hong Kong Stock Exchange. Details of the placement to a
connected client are set out below:
No.
Connected
Client
Connected
Distributor
Relationship
with
the Connected
Distributor
Basis of holding
securities
Number of
Offer Shares
(rounded
down
to nearest
whole board
lots of 50
Shares) to be
allocated to the
connected
client
Appropriate
percentage of
total number
of
Offer Shares
Approximate
percentage of
total Shares
in issue
immediately
following the
completion of
Global
Offering
1. Huatai Capital
Investment
Limited
(“HTCI”)(1)
Huatai Financial
Holdings
(Hong Kong)
Limited
(“Huatai ”)
HTCI and Huatai
are group
companies
within the
same group
Non-
discretionary
31,350 0.39% 0.04%
Notes:
1. PRC investors are currently not permitted under applicable PRC laws to participate directly in initial public
offerings ( “IPOs”) in Hong Kong. However, PRC investors are permitted to invest in products issued by
appropriate domestic securities firms licensed to undertake cross-border derivatives trading activities. In
connection with such products, the licensed domestic securities firms, through their Hong Kong affiliates,
may participate in Hong Kong IPOs either as placees or cornerstone investors (the “Cross-border
Derivatives Trading Regime ”).
Huatai Securities Co., Ltd. ( “Huatai Securities ”), the shares of which are listed on both the Shanghai Stock
Exchange (stock code: 601688) and the Hong Kong Stock Exchange (stock code: 6886), is one of the domestic
securities firms licensed to undertake cross-border derivatives trading activities. Huatai Securities entered
into an ISDA agreement (the “ISDA Agreement ”) with its indirectly wholly-owned subsidiary, HTCI, to set
out the principal terms of any future total return swap between Huatai Securities and HTCI.
Huatai is the Sole Sponsor and one of the Overall Coordinators and Underwriters in connection with the
Global Offering. Pursuant to an ISDA agreement entered into between Huatai Securities and HTCI, HTCI
will hold the beneficial interest of the Offer Shares on a non-discretionary basis as the single underlying
holding under a back-to-back total return swap ( “Huatai Back-to-back TRS ”) to be entered by HTCI in
connection with a Client TRS (as defined below) placed by and fully funded (i.e. with no financing provided
by HTCI) by Huatai Ultimate Clients (as defined below), by which, HTCI will, subject to customary fees and
commissions, pass the full economic exposure of the Offer Shares ultimately to the Huatai Ultimate Clients,
which in effect, HTCI will hold the beneficial interest of the Offer Shares on behalf of the Huatai Ultimate
Clients.


--- page 20 ---
20
HTCI and Huatai are both indirectly wholly-owned subsidiaries of Huatai Securities. Accordingly, HTCI is
considered as a “connected client ” of Huatai pursuant to paragraph 1B(7) of the Placing Guidelines.
Pursuant to the Cross-border Derivatives Trading Regime, the onshore investors ( “Huatai Ultimate Clients ”)
cannot directly subscribe for the Offer Shares but may invest in derivative products issued by domestic
securities firms licenced to undertake cross-border derivatives trading activities, such as Huatai Securities,
with the Offer Shares as the underlying assets. Instead of directly subscribing for the Offer Shares, the Huatai
Ultimate Clients, through their investment managers, will place a total return swap order ( “Client TRS ”)
with Huatai Securities in connection with the Company ’s IPO and Huatai Securities will place a Huatai Back-
to-back TRS order to HTCI on the terms of the ISDA Agreement. In order to hedge its exposure under the
Huatai Backto-back TRS, HTCI participates in the Company ’s IPO and subscribes the Offer Shares through
placing order with Huatai during the International Offering.
To the best of HTCI ’s knowledge and after making all reasonable enquiries, each of the Huatai Ultimate
Clients is an independent third party of (i) the Company, the connected person and/or their respective
associates thereof, and (ii) HTCI, Huatai and the companies which are members of the same group of HTCI.
The purpose of HTCI to subscribe for the Offer Shares is for hedging the Huatai Back-to-back TRS in
connection with the Client TRS order placed by the Huatai Ultimate Clients. Pursuant to the terms of the
contracts of the Huatai Back-to-back TRS and the Client TRS, during the tenor of the Huatai Back-to-back
TRS and the Client TRS, subject to customary fees and commissions, all economic returns of the Offer Shares
will be ultimately passed to the Huatai Ultimate Clients through the Huatai Back-to-back TRS and the Client
TRS and all economic loss shall be ultimately borne by the Huatai Ultimate Clients. HTCI will not take any
economic return or bear any economic loss in relation to the Offer Shares.
Investment in the Huatai Back-to-back TRS and the Client TRS is similar to the investment in a qualified
domestic institutional investor fund ( “QDII”) in the way that the Huatai Ultimate Clients would reap all the
economic benefits of the underlying Offer Shares, except that a QDII fund would pass through the exchange
rate exposure on both the notional value of the investment and the profit and loss of the investment. In
contrast, the profit and loss of the Huatai Back-to-back TRS and the Client TRS factor into account the
fluctuation in RMB exchange rate upon termination of the Client TRS by converting the profit and loss using
the current exchange rate at the time of termination. As such, the Huatai Ultimate Clients would bear the
exchange rate exposure of the profit and loss on settlement date.
The Huatai Ultimate Clients may exercise an early termination right to terminate the Client TRS at any
time from the issue date of the Client TRS which should be on or after the date on which the Offer Shares
are listed on the Hong Kong Stock Exchange at their own discretions. Upon the termination upon maturity
or early termination of the Client TRS by the Huatai Ultimate Clients, HTCI will dispose the Offer Shares
on the secondary market and the Huatai Ultimate Clients will receive a final settlement amount in cash in
accordance with the terms and conditions of the Huatai Back-to-back TRS and the Client TRS which should
have taken into account all the economic returns or economic loss in relation to the Offer Shares. If upon the
maturity of the Client TRS, the Huatai Ultimate Clients intend to extend the investment period, subject to
further agreement between Huatai Securities and the relevant Huatai Ultimate Clients, the term of the Client
TRS could be extended by way of a new issuance or a tenor extension. Accordingly, Huatai Securities will
extend the term of the Huatai Back-toback TRS by way of a new issuance or a tenor extension.
It is proposed that HTCI will hold the legal title and the voting right of the Offer Shares by itself, and pass
through the economic exposure to the Huatai Ultimate Clients, each being an onshore client who places a
Client TRS order with Huatai Securities in connection with the IPO of the Company. HTCI will not exercise
the voting right of the Offer Shares during the tenor of the Huatai Back-to-back TRS.
During the life of the Client TRS and Huatai Back-to-back TRS, HTCI may continue to hold the Offer
Shares in its custodian account, or to hold some or all of the Offer Shares in a prime brokerage account for
stock borrowing purposes, HTCI will lend out its holding of underlying Offer Shares in the form of stock
borrowing loans consistent with market practice to lower its finance costs, provided that HTCI has the ability
to call back the Offer Shares on loan at any time in order to satisfy its obligations under the Huatai Back-to-
back TRS to ensure the economic interests are ultimately passed to the Huatai Ultimate Clients.


--- page 21 ---
21
2. The details of the ultimate beneficial owners of Huatai Ultimate Clients are as follows:
(1) Guangzhou Haizhu Digital Economy Industrial Investment Management Co., Limited ( ᄿψ̹ऎमᅰ
ʮ̡ ) (“Guangzhou Haizhu ”) is limited liability company established in the
PRC. As of the date hereof, the sole ultimate beneficial owner of Guangzhou Haizhu is Haizhu District
Bureau of Science, Industry, Commerce and Information Technology of Guangzhou Municipality ( ᄿ
ʷ҅ ) ( “Haizhu District Bureau ”). Haizhu District Bureau is a
government body under the Guangdong Provincial Government.
(2) Shanghai Yongjin Investment Management Co., Ltd. (ʮ̡ ) is a limited
liability company established in the PRC. It acts as the fund manager of Yongjin Yongxin No.52
Private Securities Investment Fund (ग㒥 52ږ“( ) Yongxin No.52 Fund ”). As
of the date hereof, Yongxin No.52 Fund has 14 limited partners and none of them holds 30% or more
limited partnership interests.
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited
(the “Hong Kong Stock Exchange ”) and Hong Kong Securities Clearing Company Limited
(“HKSCC ”) take no responsibility for the contents of this announcement, make no representation
as to its accuracy or completeness and expressly disclaim any liability whatsoever for any
loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into
the United States (including its territories and possessions, any state of the United States and
the District of Columbia). This announcement does not constitute or form a part of any offer or
solicitation to purchase or subscribe for securities in the United States. The securities mentioned
herein have not been, and will not be, registered under the United States Securities Act of 1933,
as amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United
States except pursuant to an exemption from the registration requirements of the U.S. Securities
Act and in compliance with any applicable state securities laws, or outside the United States
unless in compliance with Regulation S under the U.S. Securities Act. There will be no public
offer of securities in the United States.
The Offer Shares are being offered and sold outside the United States in offshore transactions in
reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or
offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus.
Potential investors should read the Prospectus dated March 20, 2026 issued by Hangzhou
Diagens Biotechnology Co., Ltd. for detailed information about the Global Offering described
below before deciding whether or not to invest in the Shares thereby being offered.


--- page 22 ---
22
Potential investors of the Offer Shares should note that the Sponsor-overall Coordinator
(for itself and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their
obligations under the Hong Kong Underwriting Agreement with immediate effect upon the
occurrence of any of the events set out in the paragraph headed “Underwriting {  Underwriting
Arrangements and Expenses {  Hong Kong Public Offering {  Hong Kong Underwriting
Agreement { Grounds for Termination ” in the Prospectus at any time prior to 8:00 a.m. (Hong
Kong time) on the Listing Date (which is currently expected to be on Monday, March 30, 2026).
PUBLIC FLOAT AND FREE FLOAT
Immediately following the completion of the Global Offering and the conversion of Unlisted
Shares into H Shares, an aggregate of 46,777,043 H Shares, representing approximately 52.63%
of the total issued share capital of the Company will be held in the public hands for the purpose
of Rule 8.08 of the Listing Rules, which is higher than the prescribed percentage of H Shares
required to be held in public hands of 15% with the expected market value at the time of listing
over HK$6,000,000,000 but not exceeding HK$30,000,000,000 under the Rule 8.08(1), calculated
based on the final Offer Price of HK$99.0 per H Share, thereby satisfying Rule 19A.13A(1) of the
Listing Rules.
The Directors confirm that, immediately following the completion of the Global Offering, (i)
no placee will, individually, be placed more than 10% of the enlarged issued share capital of
the Company immediately after the Global Offering; (ii) there will not be any new substantial
Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders
do not hold more than 50% of the Shares held in the public hands at the time of the Listing in
compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300
Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday,
March 30, 2026 (Hong Kong time), provided that the Global Offering has become unconditional
and the right of termination described in the paragraph headed “Underwriting {  Underwriting
Arrangements and Expenses {  Hong Kong Public Offering {  Grounds for Termination ” in the
Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly
available allocation details prior to the receipt of H Share certificates or prior to the H Share
certificates becoming valid evidence of title do so entirely at their own risk.


--- page 23 ---
23
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. Monday, March
30, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Hong Kong Stock
Exchange will commence at 9:00 a.m. on Monday, March 30, 2026 (Hong Kong time). The H
Shares will be traded in board lots of 50 H Shares each, and the stock code of the H Shares will be
2526.
By order of our Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board and Executive Director
Hong Kong, March 27, 2026
As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng
Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr.
Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang
Jing and Mr. Wang Kaifeng as independent non-executive Directors.